Summary

Early treatment with the angiotensin receptor blocker (ARB) olmesartan significantly reduced the risk of developing microalbuminuria among patients with type 2 diabetes, according to new interim findings from the ongoing Randomized Olmesartan and Diabetes Microalbuminuria Prevention [ROADMAP] trial. However, olmesartan also appeared to increase the risk of cardiovascular mortality, raising concerns about the safety of ARBs in this patient population.